Transthyretin Amyloid Cardiomyopathy Clinical Trial
Bronx Transthyretin Amyloid Cardiomyopathy Database
Summary
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.
Eligibility Criteria
Inclusion Criteria:
All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023
Exclusion Criteria:
Did not have a transthoracic echocardiogram in our medical records
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Bronx New York, 10467, United States
How clear is this clinincal trial information?